ASCENTAGE (06855): ASCENTAGE's Lishengto successfully included in the 2026 National Reimbursement Drug List; Nailike contract renewed

ASCENTAGE (06855) announced that two of the Company's original Class 1 innovative drugs have been successfully included in the new version of the "National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" (National Reimbursement Drug List), namely: Lishengto (lisaftoclax) was included in the National Reimbursement Drug List for the first time through negotiation, for adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor. Nailike (olverembatinib) successfully renewed its contract with the National Reimbursement Drug List through renegotiation, for 1. adult patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors (TKIs); and 2. adult patients with T315I-mutated CML-CP or accelerated phase (CML-AP). As of now, all approved indications of ASCENTAGE's two innovative drugs have been included in the National Reimbursement Drug List, which will provide more patients with more accessible innovative treatment options. The new version of the National Reimbursement Drug List will be officially implemented starting January 1, 2027. Lishengto is a novel oral selective Bcl-2 inhibitor independently developed by ASCENTAGE, which restores the normal apoptotic process of cancer cells by selectively inhibiting the Bcl-2 protein, thereby achieving the purpose of tumor treatment. Lishengto was approved for marketing in China in July 2025 and is the first domestically developed original Bcl-2 inhibitor launched in China. The successful inclusion of Lishengto in the new version of the National Reimbursement Drug List will greatly enhance the medication accessibility for domestic CLL/SLL patients, enabling more patients to obtain new treatment options in a timely manner. Nailike is a novel oral third-generation BCR-ABL inhibitor independently developed by ASCENTAGE, supported by the National "Major New Drug Development" special program, and its commercial promotion in China is jointly undertaken by ASCENTAGE and INNOVENT BIO. Nailike was approved for marketing in China in November 2021 and is the first third-generation BCR-ABL inhibitor launched in China. The successful renewal of Nailike will continue to benefit more domestic CML patients and further improve the affordability and accessibility of long-term medication.